IL6 and inflammatory bowel disease: A recent publication described the development of bispecific nanobodies targeting IL-6 and TNF with additive efficacy in translational models of rheumatoid arthritis by inhibition of classic and trans-signaling of IL-6 and TNF signaling (40), a strategy that most likely will not work in IBD.